| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: Cancer J Clin, 2021,71(3): 209-249.
|
| [2] |
方友强, 周祥福. 2020版美国国立综合癌症网络前列腺癌临床实践指南要点解读[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2020, 14(6): 405-408.
|
| [3] |
Sandhu S, Moore CM, Chiong E, et al. Prostate cancer[J]. Lancet, 2021, 398(10305): 1075-1090.
|
| [4] |
Sharma BK, Kakker NK, Bhadouriya S, et al. Effect of TLR agonist on infections bronchitis virus replication and cytokine expression in embryonated chicken eggs[J]. Mol Immunol, 2020, 120: 52-60.
|
| [5] |
Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase ii study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma[J]. J Clin Oncol, 2018, 36(17): 1658-1667.
|
| [6] |
Sharma BK, Kakker NK, Bhadouriya S, et al. Effect of TLR agonist on infections bronchitis virus replication and cytokine expression in embryonated chicken eggs[J]. Mol Immunol, 2020,120: 52-60.
|
| [7] |
许青, 陆舜, 朱蕙燕, 等. 溶瘤病毒治疗恶性肿瘤临床应用上海专家共识（2021年版）[J].中国癌症杂志, 2021, 31(3): 231-240.
|
| [8] |
Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. part 1: screening, diagnosis, and local treatment with curative intent[J]. Eur Urol, 2021,79(2): 243-262.
|
| [9] |
Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37(17): 1470-1478.
|
| [10] |
Zhang H, Lin Y, Li K, et al. Naturally existing oncolytic virus m1 is nonpathogenic for the nonhuman primates after multiple rounds of repeated intravenous injections[J]. Hum Gene Ther, 2016,27(9): 700-711.
|
| [11] |
Zhang H, Li K, Lin Y, et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma[J]. Sci Transl Med, 2017, 9(404): eaam7996.
|
| [12] |
Lin Y, Zhang H, Liang J, et al. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers[J]. Proc Natl Acade Sci USA, 2014, 111(42): E4504- E4512.
|
| [13] |
Hu C, Liu Y, Lin Y, et al. Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer[J]. Cell Death Dis, 2018, 9(3): 274.
|
| [14] |
Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs[J]. Nat Rev Drug Discov, 2016, 15(9): 660.
|
| [15] |
Ichinohe T. Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design[J]. Expert Rev Vaccines, 2014, 9(11): 1315-1324.
|
| [16] |
Cai J, Zhu W, Lin Y, et al. Systematic characterization of the biodistribution of the oncolytic virus M1[J]. Hum Gene Ther, 2020, 31(21-22): 1203-1213.
|
| [17] |
Wang Y, Huang H, Zou H, et al. Liposome encapsulation of oncolytic virus m1 to reduce immunogenicity and immune clearance in vivo[J]. Mol Pharm, 2019, 16(2): 779-785.
|
| [18] |
Hu H, Tian M, Ding C, et al. The C/EBP homologous protein (CHOP) transcription factor functions in endoplasmic reticulum stress-induced apoptosis and microbial infection[J]. Front Immunol, 2019, 9: 3083.
|
| [19] |
Xiao X, Liang J, Huang C, et al. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage[J]. Nat Commun, 2018, 9(1): 4342.
|